Jefferies Forecasts $25B Peak Sales for Eli Lilly’s Weight-Loss Pill
Wall Street anticipates blockbuster demand for Eli Lilly's experimental weight-loss drug Orforglipron, with Jefferies analyst Akash Tewari projecting $25 billion in peak annual sales. The forecast eclipses Novo Nordisk's Ozempic revenues and doubles Lilly's own Mounjaro diabetes treatment.
Regulatory approval appears imminent after Lilly completed necessary clinical trials. The pharmaceutical giant plans a global launch in mid-2026, positioning the oral medication as a potential market leader in the lucrative obesity treatment sector.